Mostrando 7 resultados de: 7
Filtros aplicados
Publisher
Revista Latinoamericana de Hipertension(4)
American Journal of Therapeutics(2)
Archivos Venezolanos de Farmacologia y Terapeutica(1)
Área temáticas
Enfermedades(6)
Farmacología y terapéutica(3)
Fisiología humana(3)
Historia de América del Norte(1)
Medicina y salud(1)
Área de conocimiento
Medicamento(3)
Medicina interna(3)
Biología molecular(1)
Bioquímica(1)
Fisiología(1)
Insulin resistance and hyperinsulinemia as risk factors for cardiovascular disease
Conference ObjectAbstract: Insulin resistance is defined as a metabolic state in which insulin peripheral effects are diminishePalabras claves:Cardiovascular disease, Hiperinsulinemia, Insulin, Insulin ResistanceAutores:Acosta L., Aparicio D., Arráiz N., Canelón R., Cano R.A., Deisiree S., Finol F., Leal E.M., Linares S., Luti Y., Rojas E.R., Rojas-Quintero J., Valmore BermúdezFuentes:scopusMetabolic and hemodynamic markers of endothelial dysfunction in patients with hypertension and patients with type 2 diabetes during the cold pressor test
ArticleAbstract: Leptin, a 167-amino acid peptidic hormone secreted by adipose tissue, acts mainly in the arcuate hypPalabras claves:C-Reactive protein, Hypertension, leptin, Nitric oxide, Type 2 DiabetesAutores:Arráiz N., Cano R.A., Contreras F., Fouillioux C., Lares M., Leal E.M., Valmore Bermúdez, Velasco M.Fuentes:scopusLipoprotein (a): Molecular and Epidemiologic basis about its role in cardiovascular diseases
ReviewAbstract: In 1963, Kare Berg at the University of Oslo discovered Lp(a) as a new human plasmatic antigen set.Palabras claves:Apolipoprotein(a), Atherogenesis, Cardiovascular disease, lipoprotein(a), Lp (a), thrombogenesisAutores:Aparicio D., Arráiz N., Canelón R., Cano-Ponce C., Cizcek A., Faria J., Gotera D., Guerra-Torres X.E., Manuel V., Rojas E.R., Sorell L.T., Valmore BermúdezFuentes:scopusLipoprotein(a): From molecules to therapeutics
ReviewAbstract: Lipoprotein (a) [Lp(a)] was discovered by Kare Berg in 1963 from the study of low-density lipoproteiPalabras claves:Atherogenesis, Cardiovascular disease, Hyperlipoproteinemia(a), lipoprotein(a), therapeuticsAutores:Amell A., Aparicio D., Arráiz N., Cabrera M., Canelón R., Cano R.A., Cano-Ponce C., Faria J., Gotera D., Guerra-Torres X.E., Mengual-Moreno E., Reyna-Villasmil N., Rojas E.R., Sorell L.T., Valmore Bermúdez, Velasco M.Fuentes:scopusSerum levels of lipoprotein(a) and its behavior in the state of Zulia: 10 Years of research
ReviewAbstract: Lipoprotein Lp(a) is considered one of the most important independent risk factors for atherosclerotPalabras claves:Cardiovascular disease, Coronary artery disease, Hormone replacement therapy, lipoprotein(a), myocardial infarction, Physical activity, risk factorAutores:Amell A., Añez-Ramos R., Arias F.B., Arráiz N., Cabrera M., Cano-Ponce C., Cruz S., González M.C., Mejías J.C., Mengual-Moreno E., Nava A., Rojas-Quintero J., Silva C., Sorell G L., Souki-Rincón A., Toledo A.C., Torres W., Torres Y., Valmore BermúdezFuentes:scopusSerum lipoprotein (a) in patients post myocardial infarction
ArticleAbstract: Lipoprotein (a) [Lp (a)] is considered an independent risk factor for cardiovascular disease. In ourPalabras claves:Abdominal circumference, body mass index, dyslipidemia, Lipoprotein (a), myocardial infarctionAutores:Amell A., Añez-Ramos R., Arráiz N., Cano-Ponce C., Carem Prieto, Carrillo M., Cruz S., González M.C., Joselyn Zula, Montiel M., Salazar-Vílchez J., Silva C., Toledo A.C., Torres Y., Valmore Bermúdez, Vergara P.M.Fuentes:googlescopusPrimary dyslipidemias as risk factor for coronary heart disease
ReviewAbstract: Cardiovascular disease is the leading cause of death around the World. The Framingham's study was thPalabras claves:cholesterol, dyslipidemia, HDL-cholesterol, hypercholesterolemia, Hypertriglyceridemia, MutationsAutores:Arráiz N., Furgione A., Luti Y., Sánchez D., Scott G., Valmore Bermúdez, Velasco M.Fuentes:scopus